

APPROVED C.G. FIG.

ξ

FIG. 1






FIG. 2


08/192, 1025








- Natural Human TNF
- O Recombinant Human TNF
- ▲ Control

FIG. 3









C.G. FIG.	CLASS SUBCLASS	
APPROVED	Ъ	DRAFTSMAN




FIG. 8A




FIG. 8B

C.G. Fig.	CLASS SUBCLASS	
APPROVED	λ	DRAFTSMAN




FIG. 9A




FIG. 9B




FIG. 11




FIG. 12

C.G. FIG.	CLASS SUBCLASS	
APPROVED	≿	DRAFTSMAN




FIG. 10A




FIG. 10B

C.G. FIG.	
BY C DRAFTSMAN	

GlyPro Ser Ile Pro Leu Ile Asn Arg Pro Asp TyrHis Val Val Ala Asn Tyr Thr Ser Ala Leu Leu Ala Asn Lys 110 Glu Ala Lys Pro Trp Tyr Glu Pro Ile Ile His Val Leu Leu Thr His Tyr Leu Ile 141 Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu Ala Glu Gly Leu Ser Glu Pro Val Ala Ala Asn Asn Leu Leu Leu Ser Ala 70 Val Leu Phe Lys Gly Gln Gly Cys Pro Ser Thr Arg Ser LysArg Arg Pro Val Asp 30 Asn Lys Asp Val 130 10 90 Ser 101 Cys Gln Arg Glu Thr Pro Glu Gly Ala Trp Leu Gln Thr Gln Leu Glu Lys Gly Gln Leu Val Pro Thr Glu Gly Gln Leu Gln TyrSer Arg Asp Asn Ser Val Ala Ser Glu Leu Arg Gly Val Phe Ser Ile 21 Gln Ala Arg 61 Gln Val Ser 121 Gly Val

FIG. 13




FIG. 14A




FIG. 14B

-j <u>G</u> .	SUBCLASS	
C.G. FIG.	CLASS	
AFFROVED	B√	DRAFTSMAN
		DRAFTSMAN

Pro Asn Ala Val Val His Ala Pro Val Lys Pro Ser Asp 10 Thr Ser Arg Ser Ser Arg Val

Gly Asn Leu Leu Ala Asn Ala Ala Arg Arg Leu Asn 30 Glu Gly Gln Leu Gln Trp 21 Gln

Tyr Ser Pro Ser Glu Gly Leu Tyr Leu Ile Val Glu Leu Arg Asp Asn Gln Leu Val Val

Ile Thr His Thr Val Leu Leu His Thr Ser Pro 70 Cys Gln Gly Lys Gly Phe Leu Gln 61

Pro Ser Lys Ile 90 Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ser Ile Ala Val Arg Ser 101 81

Len $_{
m Tyr}$ Ile Glu Pro ${
m Tyr}$ Trp Pro LysAla Glu Ala Glu Gly Pro \mathtt{Thr} Glu Gln Arg Cys

Pro Asp

Ile Asn Arg

Glu

Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu Ser Ala

121

130

Len Ala Ile IleTyr Phe Gly 150 Val Gly Gln Ser Glu Ala Leu Asp Phe 141 Tyr

APPROVED C.G. FIG.

BY CLASS SUBCLASS
DRAFTSMAN

GACATCTTGCTGACTCAGTCTCCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCAGT AspileLeuLeuThrGlnSerProAlaIleLeuSerValSerProGlyGluArgValSer

TTCTCCTGCAGGCCAGTCAGTTCGTTGGCTCAAGCATCCACTGGTATCAGCAAGAACA $\tt Phe SerCysArgAlaSerGlnPhe ValGlySerSerIleHisTrpTyrGlnGlnArgThr$ AATGGTTCTCCAAGGCTTCTCATAAAGTATGCTTCTGAGTCTATGTCTGGGATCCCTTCC AsnGlySerProArgLeuLeuIleLysTyrAlaSerGluSerMetSerGlyIleProSer

AGGTTTAGTGGCAGTGGATCAGGGACAGATTTTACTCTTAGCATCAACACTGTGGAGTCT ${\tt ArgPheSerGlySerGlyThrAspPheThrLeuSerIleAsnThrValGluSer}$

GAAGATATTGCAGATTATTACTGTCAAGAAAGTCATAGCTGGCCATTCACGTTCGGCTCG ${\tt GluAspIleAlaAspTyrTyrCysGlnGlnSerHisSerTrpProPheThrPheGlySer}$

GGGACAAATTTGGAAGTAAAA GlyThrAsnLeuGluValLys FIG. 16A

C.G. FIG.	CLASS SUBCLASS	Ŋ
APPROVED	₩	DRAFTSMAN

GAAGTGAAGCTTGAGGAGTCTGGAGGAGGCTTGGTGCAACCTGGAGGATCCATGAAACTC ${\tt GluValLysLeuGluGluSerGlyGlyGlyLeuValGlnProGlyGlySerMetLysLeu}$

 ${\tt SerCysValAlaSerGlyPheIlePheSerAsnHisTrpMetAsnTrpValArgGlnSer}$ TCCTGTGTTGCCTCTGGATTCATTTTCAGTAACCACTGGATGAACTGGGTCCGCCAGTCT


CCAGAGAAGGGGCTTGAGTTGCTGAAATTAGATCAAAATCTATTAATTCTGCAACA $\tt ProGluLysGlyLeuGluTrpValAlaGluIleArgSerLysSerIleAsnSerAlaThr$


CATTATGCGGAGTCTGTGAAAGGGAGGTTCACCATCTCAAGAGAGATTCCAAAAGTGCT HisTyrAlaGluSerValLysGlyArgPheThrIleSerArgAspAspSerLysSerAla


GTGTACCTGCAAATGACCGACTTAAGAACTGAAGACACTGGCGTTTATTACTGTTCCAGG ValTyrLeuGlnMetThrAspLeuArgThrGluAspThrGlyValTyrTyrCysSerArg

AATTACTACGGTAGTACCTACGACTACTGGGGCCAAGGCACCACTCTCACAGTGTCC AsnTyrTyrGlySerThrTyrAspTyrTrpGlyGlnGlyThrThrLeuThrValSer

FIG. 16B








Patient Number

Pot cent of the Articular INDEX

Pot cent of the A




CLASS SUBCLASS

₽

C.G. FIG.

APPROVED



C.G. FIG.	CLASS SUBCLASS	
APPROVED	λa	DRAFTSMAN






FIG. 23


	Weeks	FIG. 24
	Weeks	F1G. 24
28- 20- 20- 16- 18- 4- 5creen		
(82-0) truoD trioL nallowS		


₽


Weeks	FIG. 25
e	
CRP (mg/l) 00 00 00 00 00 00 00 00 00 00 00 00 00	












CLASS SUBCLASS

₩


APPROVED O.G. FIG.

FIG. 29



APPROVED C.G. FIG.

FIG. 30







FIG. 31A






FIG. 31B

C.G. FIG.	CLASS SUBCLASS	
APPROVED	84	DRAFTSMAN




FIG. 31C

C.G. FIG.	CLASS SUBCLASS	
APPROVED	₩	DRAFTSMAN




FIG. 32




FIG. 33A





FIG. 33B

08 /1907107



p55-sf2	y=97.625-1.7489e-2x R^2=0.963	-	2000 4000	bound (cpm)	FIG. 33C
	00 00 04	20 -	0		
bound (cpm)/Free (pm)					

APPROVED C.G. FIG. BY CLASS SUBCLASS DRAFTSMAN	p75-sf2	y=196.56-2.9952e-2x R^2=0.981		-001	-	0 2000 4000 6000	(cpm)	FIG. 33F
---	---------	----------------------------------	--	------	---	------------------	-------	----------

bound (cpm)/Free(pm)

|20 | y=109.39-2.0858e-2x | R^2=0.954 | R^

08 /190, 160

C.G. FIG.	CLASS SUBCLASS	
APPROVED	ΒĄ	DRAFTSMAN

